The Hologic (Bedford, MA, USA) HPV HR test utilizes the Invader technology to detect 14 high-risk types of HPV that are associated with cervical cancer and precancerous lesions.
The US Food and Drug Administration (FDA; Silver Spring, MD, USA have approved the Cervista high throughput automation system for cervical cancer screening.

Better diagnosis and therapies have helped to reduce significantly the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV. Next to breast cancer, cervical cancer remains the second most frequent cancer affecting women worldwide.

"Our new Cervista represents a significant addition to our molecular diagnostics product portfolio," said Rob Cascella, president and CEO of Hologic. "The Cervista HTA automation system automates the HPV HR test, providing higher throughput, improved chain of custody, and accurate results. We are extremely pleased to get this product approved as it materially changes the competitive landscape for Hologic."

Related Links:
Hologic
US Food and Drug Administration